September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
8 citations
,
October 2019 in “Dermatologic Therapy” Bicalutamide improves hair density in women safely.
December 2024 in “Brazilian Journal of Hair Health” Treating both bipolar disorder and hair-related BDD with psychiatric medications improved the patient's symptoms.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
19 citations
,
March 1987 in “International Journal of Dermatology” A drug called cimetidine can help treat hair loss in women by blocking androgen receptors. However, it's not the first choice and needs more research.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
2 citations
,
January 1984 in “PubMed” Cimetidine does not significantly reduce hair growth in hirsutism.
19 citations
,
October 2013 in “Headache: The Journal of Head and Face Pain” The document concludes that inhalation of oxygen and sumatriptan injections are primary for cluster headaches, indomethacin for paroxysmal hemicrania, and lidocaine and lamotrigine for SUNCT, but SUNCT often resists treatment.
52 citations
,
January 2020 in “Scientific Reports” NLCs with manual massage greatly improve clobetasol delivery to hair follicles.
October 2016 in “Iranian journal of psychiatry and behavioral sciences” Sertraline, an antidepressant, may cause hair loss in rare cases.
April 2026 in “Brain Sciences” Finasteride may cause depression and suicidal thoughts, especially in young men.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
November 2025 in “The Journal of Sexual Medicine” Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
79 citations
,
January 2000 in “Annals of Clinical Psychiatry” Some psychiatric medications can cause hair loss, but stopping or reducing the dose usually reverses it.
47 citations
,
January 2003 in “American Journal of Clinical Dermatology” Mood stabilizers can cause serious skin reactions; careful monitoring and immediate treatment are crucial.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.
Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.
2 citations
,
May 2024 in “International Journal of Dermatology”
69 citations
,
December 2015 in “Journal of Controlled Release” Nanocapsules can improve clobetasol delivery to hair follicles, reducing side effects.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
July 2019 in “International journal of Unani and integrative medicine” Aftimoon (Cuscuta reflexa) has various health benefits, including anti-inflammatory and anticonvulsant effects.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.